MASLD and MASH
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Formerly known as nonalcoholic fatty liver disease (NAFLD), MASLD is often a silent condition where the liver becomes infiltrated with fat (steatosis), causing dysfunction at a cellular level.
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Formerly known as non-alcoholic steatohepatitis (NASH), MASH is defined as the presence of hepatic steatosis and inflammation, with or without fibrosis or scarring. MASH is a progressive condition and without intervention can lead to cirrhosis, liver cancer, and ultimately to liver failure.
MASH PATIENTS TYPICALLY DO NOT SHOW SYMPTOMS
Non-invasive tests can be performed to assess a patient for potential MASH
Fibrosis Scores
FIB-4, ELF and
other lab based tests.
Currently there are no FDA approved therapies to prevent or treat MASH, but several clinical research studies for developing treatments are available.
Contact DRI today to schedule a free FibroScan® and see if a clinical trial is right for you.
AM I AT RISK?
In adults over 50 years of age, 1 in 3 will have some form of fatty liver disease, and greater than half of all patients with type II diabetes develop MASLD or MASH.
STAGES OF LIVER DISEASE
RISK FACTORS
Can you identify with any of these conditions that put you at an elevated risk of having or developing liver disease?
Diabetes
Abnormal Cholesterol
High Triglycerides,
High HDL, Low LDL
Overweight
BMI Over 25
Post-Menopause
Alcohol Consumption
and Tobacco Use
High Blood Pressure
Over 130/80 mmHg
